ALK and non-small cell lung carcinoma: The role of targeted therapy in NSCLC brain metastases has been investigated in several clinical studies focusing on EGFR-tyrosine kinase inhibitors (gefitinib, erlotinib and afatinib) and ALK rearrangement inhibitors (crizotinib and alectinib) [28] which have shown tremendous therapeutic promise.